[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophagogastric-junction-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophagogastric-junction-adenocarcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,67,93,123,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100641511","phase-2-perioperative-fruquintinib-combined-with-sintilimab-and-sox-for-locally-advanced-gastric-or-gej-adenocarcinoma-100641511",false,"NCT07658872","Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma","Perioperative Fruquintinib Combined With Sintilimab and SOX Versus Sintilimab and SOX for Resectable Locally Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma：A Multicenter,Open-label, Randomized Controlled Phase II Clinical Study","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. Histologically confirmed gastric or gastroesophageal junction (G\u002FGEJ) adenocarcinoma.\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n4. Clinically staged as T3-4a N0-3M0 by computed tomography (CT) or magnetic resonance imaging (MRI).\n5. Considered eligible for curative resection.\n6. No prior antitumor therapy for the current disease.\n7. Adequate organ function, including hepatic, renal, and bone marrow function, as per prespecified laboratory criteria.\n8. Expected survival of ≥6 months.\n\nExclusion Criteria:\n\n1. Known mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumor.\n2. Uncontrolled hypertension, defined as systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg despite optimized antihypertensive therapy, or hypertension complicated by acute events (e.g., hypertensive crisis, hypertensive encephalopathy) that cannot be stably controlled.\n3. Tumor lesions with a bleeding tendency, including but not limited to: active ulcerative tumor lesions, hematemesis within 2 months prior to informed consent, high risk of major gastrointestinal bleeding as determined by the investigator.\n4. History of thromboembolic or arterial\u002Fvenous vascular events within 6 months prior to enrollment, such as cerebrovascular events (including transient ischemic attack), deep vein thrombosis, or pulmonary embolism.\n5. Gastrointestinal perforation or gastrointestinal obstruction within 6 months prior to enrollment.","ALL","18 Years","75 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this clinical trial is to evaluate whether perioperative fruquintinib combined with sintilimab and SOX is effective in treating locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The study will also assess the safety profile of this treatment regimen.\n\nPrimary Objective:\n\nTo determine whether perioperative fruquintinib combined with sintilimab and SOX improves the pathological complete response (pCR) rate compared with sintilimab plus SOX in patients with locally advanced gastric or GEJ adenocarcinoma.\n\nStudy Design:\n\nParticipants will be randomly assigned to receive either fruquintinib combined with sintilimab and SOX or sintilimab plus SOX to evaluate the potential added benefit of fruquintinib in this setting.\n\nParticipation Details:\n\nParticipants will receive the assigned treatment (fruquintinib combined with sintilimab and SOX or sintilimab plus SOX) every 21 days for approximately 3 months.\n\nThey will visit the clinic once every 3 weeks for evaluations, laboratory tests, and monitoring.\n\nParticipants will be asked to keep a daily diary to record any symptoms or side effects experienced during the study.",[27,28],"Gastric Adenocarcinoma","Esophagogastric Junction Adenocarcinoma",[30,31,32],"Gastric Cancer","neoadjuvant treatment","Fruquintinib","NOT_YET_RECRUITING","2026-06-15",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":34,"type":21},{"date":40,"type":21},"2028-04-06",{"name":42,"class":43},"Sichuan University","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100574635","phase-2-sintilimab-combined-with-chemotherapy-as-adjuvant-treatment-for-phase-iii-gc-and-gej-100574635","NCT06761846","Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ","A Phase II Study of Sintilimab Combined With Chemotherapy as Postoperative Adjuvant Treatment for Phase III Gastric Adenocarcinoma (GC) and The Adenocarcinoma of Esophagogastric Junction (GEJ)","Inclusion Criteria:\n\n1. Age ≥18.\n2. Patients with histopathological confirmed gastric\u002FGEJ adenocarcinoma.\n3. The pTNM is confirmed between IIIA-IIIC and the PD-L1 CPS\\>=1.\n4. Patients treated with D2 surgery.\n5. ECOG is 0 or 1.\n6. Patients who could tolerate chemotherapy combined with immunotherapy.\n7. Patients who are not pregnant and have no willing to get pregnant within 6 months after the treatment is over.\n8. Patients who are willing to offer their postoperative tumor tissue and their peripheral blood samples.\n9. Patients who are volunteer to sign the ICF.\n\nExclusion Criteria:\n\n1. Patients who had received neoadjuvent treatments before surgery.\n2. Patients who have discovered tumor relapse or metastasis before adjuvent treatment.\n3. Patients who have other malignant tumors.\n4. Patients who could not swallow the tablets and capsules.\n5. Other conditions which the researchers think are not suitable for participate the study.",{"count":52,"type":21},70,[24],"This study is a prospective, single-arm, phase II clinical study. Screening patients with stage III GC\u002FGEJ adenocarcinoma after D2 or broader radical resection. After enrolling in the study, the subjects receive Sintilimab combined with oxaliplatin+Tegafur, Gimeracil and Oteracil Potassium Capsules (SOX) or oxaliplatin+Capecitabine (XELOX) , in which the combined chemotherapy is up to 8 cycles, and the total course of treatment was 16 cycles. The following-up of subjects includes adverse events、disease status、living conditions and the quality of life.",[27,28],"RECRUITING","2026-04-19",{"date":59,"type":37},"2026-04-21",{"date":61,"type":37},"2025-01-17",{"date":63,"type":21},"2028-12-31",{"name":65,"class":43},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":66},"100551578","phase-2-efficacy-and-safety-of-anti-pd-1-thymalfasin-and-sox-in-neoadjuvant-treatment-of-cstage-iii-gastricgastroesophageal-junction-adenocarcinoma-100551578","NCT06461910","Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric\u002FGastroesophageal Junction Adenocarcinoma","The Efficacy and Safety of Anti-PD-1 Combined With Thymalfasin and SOX in Neoadjuvant Treatment of cStage III Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Open-label, Single-arm, Phase II Clinical Study","Inclusion Criteria:\n\n* Age and Diagnosis:\n\nPatients aged 18-75 years with gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma, regardless of gender.\n\n* Stage and Diagnosis Confirmation:\n\nAccording to the 8th edition of AJCC staging for gastric cancer, patients must be assessed via abdominal CT as cStage III (cT3-4aN1-3M0).\n\nDiagnosis must be confirmed by endoscopy and pathology as G\u002FGEJ adenocarcinoma (HER-2 negative).\n\nOnly patients with Siewert type III and type II (who do not require combined thoracic surgery) GEJ cancer are eligible.\n\n* Surgical Assessment:\n\nTumors must be deemed resectable with curative intent (R0 resection) as determined by a gastrointestinal surgeon and a radiologist.\n\nPatients must agree to undergo radical surgery and be deemed operable by a surgeon.\n\n* Previous Treatments:\n\nPatients must not have received prior systemic treatment for the current disease, including surgery, anti-tumor chemotherapy, radiotherapy, or immunotherapy.\n\n* Survival Expectancy:\n\nExpected survival of at least 3 months.\n\n* Measurable Disease:\n\nTumors must be measurable according to RECIST v1.1 criteria.\n\n* Performance Status:\n\nECOG PS score of 0-1 within 7 days prior to the first dose.\n\n* Cardiac Function:\n\nGood cardiac function, suitable for curative surgery. Preoperative evaluation by a cardiologist is required if there are clinical indications of underlying ischemic, valvular, or other severe heart diseases.\n\n* Organ Function:\n\nNormal function of major organs, meeting the following laboratory criteria:\n\nAbsolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL without granulocyte colony-stimulating factor for the past 14 days.\n\nPlatelet count ≥ 100 x 10\\^9\u002FL without transfusion for the past 14 days. Hemoglobin \\> 9 g\u002FdL without transfusion or erythropoietin use for the past 14 days.\n\nTotal bilirubin ≤ 1.5 x upper limit of normal (ULN); if \\> 1.5 x ULN, direct bilirubin must be ≤ ULN.\n\nAST and ALT ≤ 2.5 x ULN. Serum creatinine ≤ 1.5 x ULN and creatinine clearance (using Cockcroft-Gault formula) ≥ 60 ml\u002Fmin.\n\nNormal coagulation function (INR or PT ≤ 1.5 x ULN). Normal thyroid function (TSH within normal range, or normal T3\u002FFT3 and FT4 if baseline TSH is out of range).\n\nNormal myocardial enzyme spectrum (clinical judgment for non-significant lab abnormalities is acceptable).\n\n* Weight:\n\nBody weight ≥ 40 kg or BMI \\> 18.5.\n\n* Female Patients:\n\nMust be post-menopausal (no menses for at least one year without other causes) or surgically sterilized (removal of ovaries and\u002For uterus).\n\nWomen of childbearing potential must have a negative pregnancy test within 7 days prior to the first dose.\n\nAgree to use highly effective contraception (annual failure rate \\\u003C 1%) or abstain from heterosexual intercourse from the time of informed consent until at least 120 days after the last dose of the study drug or 9 months after surgery.\n\n* Male Patients:\n\nMust agree to use contraception or abstain from heterosexual intercourse from the time of informed consent until at least 120 days after the last dose of the study drug or 9 months after surgery.\n\nRegular abstinence (e.g., calendar, ovulation, basal body temperature, or post-ovulation methods) and withdrawal are not acceptable forms of contraception.\n\n* Informed Consent:\n\nPatients must read, understand, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Other Malignancies:\n\nPatients with a history of other malignancies within the past 5 years or concurrent malignancies. Exceptions include cured localized tumors such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ prostate cancer, in situ cervical cancer, in situ breast cancer, stage I lung cancer, and stage I colorectal cancer.\n\nTransplant Patients:\n\nPatients planning to undergo or having previously undergone organ or bone marrow transplantation.\n\nBlood Transfusions and Bleeding:\n\nPatients who have received a blood transfusion within 2 weeks before the first dose, have a history of bleeding, or experienced any severe bleeding events (grade 3 or higher per CTCAE 4.0) within 4 weeks before screening.\n\nCoagulation Disorders:\n\nPatients with coagulation abnormalities and bleeding tendencies (INR \\> 1.5 without anticoagulants). Patients on anticoagulants or vitamin K antagonists like warfarin, heparin, or similar drugs can participate if INR ≤ 1.5, small-dose warfarin (1 mg\u002Fday) or aspirin (≤ 100 mg\u002Fday) is allowed for preventive use.\n\nThromboembolic Events:\n\nPatients with arterial\u002Fvenous thromboembolic events within 6 months before screening, such as stroke (including transient ischemic attacks), deep vein thrombosis (excluding cases resolved post-chemotherapy), and pulmonary embolism.\n\nCardiac Conditions:\n\nPatients with myocardial infarction, uncontrolled arrhythmias (including QTc interval ≥ 450 ms for males and ≥ 470 ms for females, using the Fridericia formula) within 6 months before the first dose.\n\nNYHA class III-IV heart failure or LVEF \\\u003C 50% on echocardiogram.\n\nProteinuria:\n\nUrinalysis indicating proteinuria ≥ ++ and 24-hour urine protein \\> 1.0 g.\n\nOral Drug Absorption Issues:\n\nFactors affecting oral drug absorption (e.g., inability to swallow, chronic diarrhea, bowel obstruction).\n\nPleural or Peritoneal Effusion:\n\nClinically significant pleural or peritoneal effusion requiring intervention.\n\nHIV Infection:\n\nPatients with HIV infection.\n\nActive Tuberculosis:\n\nPatients with active tuberculosis.\n\nNon-Healing Wounds or Fractures:\n\nPatients with long-standing unhealed wounds or incomplete healing of fractures.\n\nLung Diseases:\n\nPatients with interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severely impaired lung function that could interfere with the detection and treatment of suspected drug-related pulmonary toxicity.\n\nAutoimmune Diseases:\n\nPatients with known active or suspected autoimmune diseases, except those in a stable state without systemic immunosuppressive treatment.\n\nChronic Autoimmune Diseases:\n\nSevere chronic autoimmune diseases such as systemic lupus erythematosus; patients with a history of ulcerative colitis, Crohn's disease, or irritable bowel syndrome; history of sarcoidosis or tuberculosis; active hepatitis B or C, and HIV infection.\n\nWell-controlled non-severe autoimmune diseases like dermatitis, arthritis, psoriasis can be included. Patients with hepatitis B virus titers \\\u003C 500 copies\u002Fml can participate.\n\nImmunosuppressive Treatment:\n\nPatients requiring systemic corticosteroids (\\> 10 mg\u002Fday prednisone equivalent) or other immunosuppressive drugs within 14 days before the first dose or during the study. Localized topical or inhaled steroids or adrenal hormone replacement therapy (≤ 10 mg\u002Fday prednisone equivalent) are allowed.\n\nActive Infections:\n\nActive infections requiring systemic treatment within 14 days before the first dose. Preventive antibiotic treatment (e.g., for urinary tract infection or COPD) is allowed.\n\nLive Vaccines:\n\nPatients who have received live vaccines within 28 days before the first dose. Inactivated viral vaccines for seasonal flu are allowed.\n\nPrevious Checkpoint Inhibitors:\n\nPatients previously treated with checkpoint inhibitors like PD-1, PD-L1, or CTLA-4 inhibitors.\n\nImmunomodulatory Treatments:\n\nPatients who received immunomodulatory treatments (e.g., thymopentin, thymalfasin, interferons, CAR-T therapy) within 6 months before the first dose.\n\nOther Clinical Studies:\n\nPatients currently receiving other clinical study treatments or planning to start this study treatment within one month of completing a previous clinical study treatment.\n\nDrug Allergies:\n\nKnown allergy or intolerance to any study drug or its components.\n\nSubstance Abuse:\n\nHistory of alcohol, drug, or substance abuse. Patients who have stopped drinking can be included.\n\nCompliance Issues:\n\nPatients who are non-compliant with medical instructions, prescribed medications, or have incomplete records affecting efficacy or safety assessments.\n\nPregnancy and Breastfeeding:\n\nPregnant or breastfeeding women.\n\nHigh-Risk Factors:\n\nPatients with conditions increasing the risk of study participation or study drug use, or other severe, acute, or chronic diseases deemed unsuitable by the investigator.\n\nInvestigator Discretion:\n\nAny other conditions that the investigator deems unsuitable for the clinical trial.",{"count":75,"type":21},30,[24],"This Phase II clinical study is a prospective, open-label, single-arm trial designed to evaluate the efficacy and safety of combining anti-PD-1 therapy (Serplulimab) with thymalfasin and the SOX chemotherapy regimen as a neoadjuvant treatment for patients with clinical stage III gastric or gastroesophageal junction(GEJ) adenocarcinoma.",[30,28],[80,81,82,83],"neoadjuvant","PD-1","Thymalfasin","Chemotherapy","2026-02-28",{"date":86,"type":37},"2026-03-03",{"date":88,"type":37},"2024-06-14",{"date":90,"type":21},"2027-12",{"name":92,"class":43},"Zekuan Xu",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100597500","phase-1-a-phase-ib-trial-evaluating-the-safety-and-activity-of-neoadjuvant-combination-of-tislelizumab-plus-flot-for-resectable-esophagogastric-adenocarcinoma-100597500","NCT07059299","A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma","NeoTISLEGA - A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma","NeoTISLEGA","Inclusion Criteria:\n\n1. Patient\\* has given written informed consent.\n2. Patient is ≥ 18 years of age at time of signing the written informed consent.\n3. Patient has histologically proven locally advanced (cT2-4 , any cN , M0 OR any cT, cN+, M0 stage) gastric, esophageal or esophagogastric junction adenocarcinoma that:\n\n   1. Is considered technically resectable.\n   2. Does not involve distant site of the peritoneal cavity.\n\n      * confirmed by diagnostic laparoscopy for all patients with tumors located in the stomach and those with type 2 and 3 GEJ adenocarcinomas according to ESMO guideline recommendation \\[Lordick et al. 2022\\].\n      * Type 1 GEJ and esophageal adenocarcinomas can be enrolled without diagnostic laparoscopy (which is in line with guidelines and the current routine practice in Germany).\n4. Tumor material is available for local assessment of PD-L1 (CPS) and dMMR\u002FMSI-status at the investigator´s site.\n5. Patient has an ECOG performance status 0 or 1.\n6. Patients has adequate blood count, liver-enzymes, and renal function:\n\n   1. ANC (Absolute neutrophil count) \\> 1,500 cells\u002FμL without the use of hematopoietic growth factors.\n   2. Platelet count ≥ 100 x 10\\^9\u002FL (\\>100,000 per mm3).\n   3. Hemoglobin ≥ 9 g\u002FdL.\n   4. Serum total bilirubin ≤ 1.5x institutional upper normal limit (ULN).\n   5. AST (SGOT)\u002FALT (SGPT) ≤ 2.5 x institutional ULN.\n   6. Patients not receiving therapeutic anticoagulation must have an INR ≤ 1.5 ULN and aPTT ≤ 1.5 ULN. The use of full dose anticoagulants is allowed (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of inclusion.\n   7. Serum Creatinine ≤ 1.5 x ULN and a calculated creatinine clearance rate ≥ 50 mL \u002Fmin.\n7. Female patients defined as women of childbearing potential (WOCBP) must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \\\u003C 1% per year during the treatment period and for 4 months after last dose of tislelizumab or 6 months after the last dose of chemotherapy, whatever is later. Male patients with WOCBP partners must agree to remain abstinent (refrain from heterosexual intercourse) or use barrier contraceptives during the above period. Furthermore, male patients must refrain from donating sperm during this same period.\n\n   * There are no data that indicate special gender distribution. Therefore, patients will be enrolled gender-independently in this trial.\n\nExclusion Criteria:\n\n1. Patient received previous (radio)chemotherapy or immunotherapy for the same condition or within the past five years for any other cancerous condition.\n2. Patient received prior partial or complete esophagogastric resection.\n3. Patient has known hypersensitivity to any component of the tislelizumab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein and\u002For any known contraindication (including hypersensitivity) to one of the study drugs.\n4. Patient has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n5. Patient has lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within three months of the study randomization, severe asthma, severe COPD, restrictive lung disease, pleural effusion etc.).\n6. Patient has inadequate cardiac function (LVEF value \\\u003C 50 %) as determined by echocardiography.\n7. Patient has a known complete absence of dihydropyrimidine dehydrogenase (DPD) activity.\n8. Patient received treatment with brivudine, sorivudine or their chemically related analogues within 28 days prior to study enrollment.\n9. Patients has pernicious anemia or other megaloblastic anemia due to vitamin B12 deficiency.\n10. Patient has peripheral sensitive neuropathy with functional deficits.\n11. Patient has a medical history of myocardial infarction (MI) within 6 months before enrollment, symptomatic congestive heart failure (CHF; New York Heart Association Class II to IV). Subjects with troponin levels above ULN at screening (as defined by the manufacturer), and without any MI related symptoms should have a cardiologic consultation during screening to rule out MI.\n12. Patient has a corrected QT interval (QTc) prolongation to \\> 470 ms (females) or \\>450 ms (males) based on average of the screening triplicate12-lead ECG.\n13. Participant has a known additional malignancy that is progressing or has required active treatment within the past 2 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n14. Patient has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.\n15. Patient has active primary immunodeficiency, known uncontrolled active HIV infection or active hepatitis B or C (HBV\u002FHCV) infection. Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA. Subjects with past or resolved HBV infection are eligible only if they meet all of the following criteria:\n\n    * HBsAg(-) (for \\> 6 months off anti-viral treatment)\n    * Anti-HBc(+) (IgG or total Ig)\n    * HBV DNA undetectable\n    * Absence of cirrhosis or fibrosis on prior imaging or biopsy\n    * Absence of HCV co-infection or history of HCV co-infection\n    * Access to a local hepatologist during and after the study\n16. Patient has active or history of autoimmune disease including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener's granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n17. Patient received treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within four weeks or five half-lives of the drug, whichever is longer, prior to study enrollment.\n18. Patient received treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to study enrollment. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed.\n19. Patient received prior allogeneic bone marrow transplantation or prior solid organ transplantation.\n20. Patient received live, attenuated vaccine within 30 days prior initiation of study drug.\n21. Patient has any other serious concomitant or medical condition that, in the opinion of the investigator, presents a high risk of complications to the patient or reduces the likelihood of clinical effect.\n22. Patient participated in another interventional clinical study according to Medicines Act within 28 days prior to study enrollment or participation in a clinical study according to Medicines Act at the same time as this study unless it is an observational \u002F non-interventional study or during the follow-up period of an interventional study.\n23. Patient has taken an investigational drug within 28 days prior to initiation of study drug.\n24. Female patients, who are pregnant or breast feeding or planning to become pregnant within 7 months after the last dose of study treatment. Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment.",{"count":102,"type":21},18,[104],"PHASE1","With this trial, we aim to evaluate a new combination therapy with tislelizumab and FLOT chemotherapy before surgery (neoadjuvant) for locally advanced, resectable adenocarcinoma of the esophagus or stomach (EGA). The aim of this phase Ib trial is to determine whether this combination is safe and clinically active enough to support the continuation of this concept in subsequent trials investigating novel drug combinations in the neoadjuvant setting of locally advanced EGA. As many patients are unable to tolerate the postoperative part of the standard therapy concept, we aim here to assess a prolongation of preoperative therapy to 6 or 8 applications of FLOT, instead of the routinely administered 4 pre- and 4 postoperative applications, in combination with tislelizumab.",[28,27,107,108,109],"Esophageal Adenocarcinoma","Resectable Esophagogastric Adenocarcinoma","Neoadjuvant Therapy",[111,112,113,80],"gastric cancer","FLOT","Tislelizumab","2025-12-12",{"date":116,"type":37},"2025-12-19",{"date":114,"type":37},{"date":119,"type":21},"2027-08",{"name":121,"class":43},"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest",4,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":66},"100452361","phase-2-neoadjuvant-immunochemotherapy-in-locally-advanced-esophagogastric-junction-adenocarcinoma-100452361","NCT05170503","Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma","Neoadjuvant Sintilimab Plus SOX in the Locally Advanced Esophagogastric Junction Adenocarcinoma: a Prospective, Single Arm Phase II Trial","Inclusion Criteria:\n\n* Histologically confirmed locally advanced esophagogastric junction Adenocarcinoma cT3-4aN0 or T1-4aN1-3M0\n* No previous anti-tumor treatment\n* ECOG PS: 0-1\n* The functions of important organs meet the following requirements (excluding the use of any blood components and cell growth factors during the screening period)：Absolute neutrophil count ≥ 1.5 × 109\u002FL； Platelet ≥ 90 × 109\u002FL； Hemoglobin ≥ 9g \u002F dl; Serum albumin ≥ 3G \u002F dl; Thyroid stimulating hormone (TSH) ≤ ULN (if abnormal, the levels of T3 and T4 should be investigated at the same time. If the levels of T3 and T4 are normal, they can be included in the group); Bilirubin ≤ ULN; ALT and AST ≤ 1.5 times ULN; AKP ≤ 2.5 times ULN; Serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 60ml \u002F min.\n* Women of childbearing age must have taken reliable contraceptive measures or conducted pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and are willing to use appropriate contraceptive methods during the test and 8 weeks after the last administration of test drugs. For men, they must agree to use appropriate methods of contraception or surgical sterilization during the trial and 8 weeks after the last administration of the trial drug.\n* The patients voluntarily joined the study and signed the informed consent form. They had good compliance and cooperated with the follow-up.\n\nExclusion Criteria:\n\n* Known Her-2 positive\n* Any active autoimmune disease or history of autoimmunity (as follows, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism and hypothyroidism; Subjects with vitiligo or asthma in childhood have been completely relieved and do not need any intervention after adulthood can be included; Asthma in which subjects need bronchodilators for medical intervention cannot be included).\n* Severe allergic reaction to monoclonal antibody.\n* The number of neutrophils in peripheral blood was less than 1500 \u002F mm3.\n* There are cardiac clinical symptoms or diseases that are not well controlled.\n* Previously received radiotherapy, chemotherapy, hormone therapy, surgery or molecular targeted therapy.\n* The subjects were innate or acquired immunodeficiency (such as HIV), or active hepatitis (hepatitis B reference: HBsAg) positive, HBVDNA \\> 2000IU\u002Fml or copy number \\> 104\u002Fml; Hepatitis C reference: HCV antibody positive.\n* According to the judgment of the researcher, the subject has other factors that may lead to the forced midway termination of this study, such as other serious diseases (including mental diseases) requiring combined treatment, serious laboratory abnormalities, accompanied by family or social factors, which will affect the safety of the subject, or the collection of data and samples.\n* The researchers judged the patients with high risk of esophageal perforation or no potential possibility of surgery through endoscopic ultrasonography or imaging.",{"count":131,"type":21},37,[24],"The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (Tegafur+Oxaliplatin) for locally advanced esophagogastric junction adenocarcinoma.",[28],[28,80,136,137],"chemo-immunotherapy","Sintilimab","2025-06-08",{"date":140,"type":37},"2025-06-12",{"date":142,"type":37},"2021-12-29",{"date":144,"type":21},"2029-01-01",{"name":146,"class":43},"Sun Yat-sen University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":66},"100553184","phase-2-perioperative-treatment-of-resectable-adenocarcinoma-of-esophagogastric-junction-by-immunotherapy-adebrelimab-combined-with-chemotherapy-xelox-a-prospective-single-center-feasibility-study-100553184","NCT06482788","Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study","AEGIS","Inclusion Criteria:\n\n* Sign on the informed consent form (ICF)\n* Histologically confirmed esophagogastric junction Adenocarcinoma (AEG, Type Siewert I\u002FII\u002F III), the stage is locally advanced cT1b-2N+ or T3-4Nany that the investigator judges it to be resectable (1. CT or MRI assessment shows no invasion of adjacent organs or tissues, 2. No peritoneal metastasis occurs, 3. There are surgical indications) (Note: If bone lesions are suspected, a bone scan is required; if peritoneal carcinomatosis is suspected, laparoscopy is required to confirm; if T3-T4 subjects have diffuse tissue types, diagnostic laparoscopy is also required))\n* No previous systematic treatment\n* At least one measurable lesion according to RECIST 1.1.\n* ECOG PS: 0-1\n* The functions of important organs meet the following requirements：Absolute neutrophil count ≥ 1.5 × 109\u002FL； Platelet ≥ 100 × 109\u002FL； Hemoglobin ≥ 90g \u002F l; ALT and AST ≤ 2.5 times ULN; TBIL ≤ 1.5 times ULN; Serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 60ml \u002F min; INR ≤ 1.5, APTT ≤ 1.5 times ULN; No obvious abnormality on electrocardiogram.\n* Male subjects and women of childbearing age must take contraceptive measures from the first dose to the last 3 months of use of the study drug.\n\nExclusion Criteria:\n\n* Histologically confirmed Squamous cell carcinoma or mixed type.\n* Distant metastasis: If peritoneal cancer or ascites is suspected by imaging, histological or cytological confirmation such as laparoscopic exploration is required.\n* Medical history and complications: 1.Having contraindications to surgical resection of esophagogastric junction cancer 2.Having any known active autoimmune diseases 3.Having any complications that require systemic treatment with glucocorticoids such as prednisone (\\>10 mg\u002Fday) or have used immunosuppressive drugs within 14 days before the first dose\n* Having received tumor vaccines or other immune-activating anti-tumor drugs (such as interferon, interleukin, thymosin or immune cell therapy) within 1 month before the first dose 4.Having participated in other clinical trials or have received drug interventions from other clinical trials within 4 weeks before the first dose 5.Having other malignant tumors that need treatment 6.Having a history of severe cardiovascular disease 7.Having a known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation\n* Severe allergic reaction to drugs (Adbrelimab, Capecitabine, Oxaliplatin).\n* The subjects were innate or acquired immunodeficiency (such as HIV), or active hepatitis (hepatitis B reference: HBsAg) positive; Hepatitis C reference: HCV antibody positive.\n* According to the judgment of the researcher, the subject has other factors that may lead to the forced midway termination of this study, such as other serious diseases (including mental diseases) requiring combined treatment, serious laboratory abnormalities, accompanied by family or social factors, which will affect the safety of the subject, or the collection of data and samples.",{"count":155,"type":21},26,[24],"The purpose of this study is to explore the effectiveness and safety of immunotherapy (Adebrelimab, a PD-L1 inhibitor) combined with standard chemotherapy (XELOX) in the perioperative treatment of resectable esophagogastric junction adenocarcinoma.",[28],"2024-06-27",{"date":161,"type":37},"2024-07-01",{"date":163,"type":37},"2024-05-22",{"date":165,"type":21},"2027-05-31",{"name":167,"class":43},"Ruijin Hospital"]